COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Fulvestrant as Maintenance Therapy After First-line Chemotherapy in HER2 - Postmenopausal MBC Patients (FUMANCE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02383030
Recruitment Status : Unknown
Verified June 2016 by Consorzio Oncotech.
Recruitment status was:  Recruiting
First Posted : March 9, 2015
Last Update Posted : June 15, 2016
Clinical Research Technology S.r.l.
Information provided by (Responsible Party):
Consorzio Oncotech

No Study Results Posted on for this Study
Recruitment Status : Unknown
Estimated Primary Completion Date : September 2017
Estimated Study Completion Date : December 2017